Tech Company Financing Transactions
Nuclidium Funding Round
Angelini Ventures, Kurma Partners and Bayern Kapital joined a $33 million Series B funding round for Nuclidium. The round was announced on 5/27/2026.
Transaction Overview
Company Name
Announced On
5/27/2026
Transaction Type
Venture Equity
Amount
$33,000,000
Round
Series B
Investors
Angelini Ventures (Lead Investor)
Kurma Partners (Lead Investor)
Proceeds Purpose
The Series B extension and support from our world-class investors further validate our strategy to advance next-generation copper-based radiotheranostics and unlock the full potential of the theranostic modality.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Im Erasmushaus, Bäumleingasse 18
Basel, 4051
Switzerland
Basel, 4051
Switzerland
Phone
Undisclosed
Website
Email Address
Overview
NUCLIDIUM's vision is to address the unmet need in cancer medicine by providing personalised treatment options for cancer patients at every stage of their disease to improve long-term survival. Our therapeutic approach combines accurate diagnosis and staging of cancers at an early stage with a highly personalized treatment dose enabling less aggressive treatment and a significantly better quality of life for the patient.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Leila Jaafar-Thiel
Browse more venture capital transactions:
Prev: 5/27/2026: Thea Energy venture capital transaction
Next: 5/28/2026: RepAI venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs